HCV R&D and Business Development Database

HCV R&D and Business Development Database

This unique CD-ROM database product is one of the most comprehensive and up to date information sources on chronic hepatitis C virus R&D and business development. The database contains extensive corporate, R&D, and business collaboration information. The company profile database covers over 150 companies from 18 different countries. The R&D database covers over 160 pipeline drugs from early stage as target validation to late stage as phase III. All projects have as far as possible been assigned with specified targets, such as IMPDH, RdRp, P7 etc, and mechanism, such as anti-fibrotic, antisense, immune modulator etc. In the collaboration database more than 80 unique business collaborations have been described. Read more about general and specifics about each database below.

"HCV R&D and Business Development Database" is also the basis for the analytical report Competitive Outlook on HCV: What to Know & Expect in R&D and Business Development. Both this products are included in the Analytical Tool Competitive Outlook in HCV

The "HCV R&D and Business Development Database " is a collection of three databases: Company Profiles, R&D Projects and Business Collaborations

This database product is acquired as a stand-alone database, and no subscription is required.

Contents

Please note that due to the nature of this report, no Table of Contents is available.

Related products

The Epigenetics Healthcare R&D, Products and Commercial Implications Tools, Technologies, Equipment, Opportunities & Emerging WW Market Outlook This report presents information about the quickly emerging worldwide epigenetics market. This important life science market includes key product areas that will have a powerful impact on current and...

Strategies for Innovation in Pharmaceutical R&D Enhancing R&D Through Biotech Alliances and CRO Outsourcing This new report has been written to provide members of pharmaceutical, biotechnology and clinical research sectors an analytically-based overview of the mechanisms of the partnering process, and the key issues...

Siemens AG Product Pipeline Analysis Siemens AG Product Pipeline Analysis Summary This report is an insightful source for data, analysis and strategic insights into a Scope's pipeline and investigational products. The report also provides details on clinical...

Practical Systems Biology Demonstrating Value Today in Pharma R&D This Health Industry Insights Perspective provides insights on the practical use of systems biology solutions to advance and accelerate drug development in the life sciences industry. Since its conceptualization in...

Decoding Big Pharmas R&D Strategy in Oncology This report, Decoding Big Pharma's R&D Strategy in Oncology, is based on five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Between them and...

Translational Medicine in Biopharmaceutical R&D Enabling R&D optimization and early detection of potential failures As the pharma industry continues to experience rising research costs, drug failures and low returns on investment, companies who are increasingly facing major patent expiries and scarcely populated late-stage pipelines...

Who's Doing What in Molecular Diagnostics? Kalorama / Emmes Survey of US Laboratories From Kalorama Information a unique tool for assessing the diagnostic business today. Working in conjunction with premier diagnostic survey database Emmes Group, Kalorama Information presents the summarized results from...

Molecular Diagnostics: a primer on an emerging sector Introduction This report analyzes the emerging sector of molecular diagnostics. It provides a clear classification, assessing the leading technologies and key tests which are positioned in this exciting area of diagnostics....

Molecular Imaging in Drug R&D and Medical Practice Technologies, Applications, Markets The rapidly emerging field of molecular imaging is poised to open new vistas for basic researchers, scientists working in drug discovery and development, and physicians. This new report delves fully...

Competitive Outlook on HCV What to Know & Expect in R&D and Business Development The competitive business environment for the pharmaceutical market of chronic hepatitis C virus (HCV) infection is fierce and changing. The entry of Hoffmann-La Roche into this $3 billion market, previously...

Strategic Management of Resources and Portfolios Structuring Risk to Maximize Opportunity in Pharmaceutical R&D As a company develops its business, resources will always be limited and risk will always be involved. This is especially true for companies operating in the high-risk life science industry....

Antibiotic R&D Resolving the Paradox between Unmet Medical Need and Commercial Incentive The current crisis in antibiotic R&D is attributed to an industry pipeline with few late-stage candidates capable of combating the emergence and spread of novel, drug-resistant bacterial strains. This new...

Life Science Tools and Technologies for Bio-Pharma R&D Instruments, Tech Platforms, Informatics and Market This market research report is about the important market for life science tools & techs that are used for accelerating the research processes and capabilities of biopharmaceutical R&D. This...

Analytical Tool: Competitive Outlook on HCV BioSeeker Group's "Analytical Tool: Competitive Outlook on HCV", represents a powerful product combination of the independent and unbiased analytical report Competitive Outlook on HCV: What to Know & Expect in...

Scrip R&D Databook 2006 Parallel trade is the process by which goods protected by an intellectual property right, such as a patent or trademark, placed in circulation in one market, are imported into a...

Decoding Big Pharma's R&D Strategy in Oncology This report, Decoding Big Pharma's R&D Strategy in Oncology, is based on five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Between them and...

Cancer Therapeutics Market Insight and R&D Pipeline Analysis Objectives and Scope The intention of this study is to provide a detailed and thorough analysis of the present and future global market for cancer therapeutics. This report analyzes in detail...

The Global Antivirals Market R&D Pipelines, Market Analysis and Competitive Landscape The global anti-infective market is currently valued at US$66.5 billion with antiviral agents accounting for 24% of sales (excluding vaccines which target viral infectious diseases). According to Arrowhead Publishers' new report...

RNA Interference for Drug R&D Applications, Alliances, Companies and WW Market to 2011 This report assesses the RNA interference market for drug R&D. RNA interference (RNAi) has been hailed in the science media as the hottest technical breakthrough in bioscience in the last...

China Antibodies & Database Package With a rapidly growing economy, cost advantages, a skilled workforce, and a governmental commitment to the sciences, China is becoming increasingly important in the global biotechnology industry. Successful forays into...

Innovative Drug R&D in China As Chinese pharmaceutical industry is rising rapidly, a growing number of Chinese drug companies pay attention to investing in research of innovative medicines. Their attempts are encouraged by government who...

Research & Development in the Pharmaceutical Industry Options for success The pharmaceutical industry is one of the most successful industries in the technology sector and its ability to innovate has seen it launch nearly 1,400 new chemical entities as human...

New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency With industry consolidation, the economic downturn, and an increasing threat from generics, pharma companies are coming under greater pressure to fill their pipelines with innovative drugs. However, despite the costs...

View all products in this category